10 results
6-K
EX-99.2
PHXM
PHAXIAM Therapeutics S.A.
25 Oct 23
Current report (foreign)
9:21am
by Staphylococcus aureus
Approval of study design by French ANSM and Ethics Committee
Recruitment of 12 patients expected to start in Q4 2023 in 4 French centers
6-K/A
EX-99.1
PHXM
PHAXIAM Therapeutics S.A.
12 Sep 22
I.Certification of the Person Responsible for the Half-year Financial Report
4:33pm
flow, it has been announced in November 2021 that recruitment of new patients in this study will be stopped. In September 2022, TRYbeCA-2 trial’s
6-K
EX-99.1
PHXM
PHAXIAM Therapeutics S.A.
12 Sep 22
I.Certification of the Person Responsible for the Half-year Financial Report
12:04pm
announced in November 2021 that recruitment of new patients in this study will be stopped. [On September 12, 2022, the Company reported negative results … with the patients enrolled prior to the end of recruitment in TRYbeCA-2, with eryaspase not providing clinical benefit in the trial.]
In addition
6-K
EX-99.1
PHXM
PHAXIAM Therapeutics S.A.
20 Sep 21
I.Certification of the Person Responsible for the Half-year Financial Report
1:37pm
of recruitment and interim analysis occurred in January 2021 and February 2021, respectively.
Substantial additional financing will be needed by the Company
6-K
EX-99.1
uxp44n
9 Mar 21
ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2020
9:55am
20-F
wi4kfvrgb s3c3s
24 Apr 18
Annual report (foreign)
12:00am
- Prev
- 1
- Next